Calidi Biotherapeutics, Inc. (CLDI) - Dilution Analysis

10-Q filing | 19.3M shares outstanding

8-K filing: Calidi Biotherapeutics, Inc. issued a warrant to purchase up to 17,391,304 shares of common stock with an exercise price of $0.23 to an accredited investor in a private placement transaction.

10-Q filing | 7.2M shares outstanding

8-K filing: Calidi Biotherapeutics, Inc. sold 22,500,000 shares of Nova Cell common stock, representing 75% equity interest and 100% ownership, to Nova Cell for $6,000,000. ($6.0M proceeds)

8-K filing: Calidi Biotherapeutics, Inc. completed an offering of common stock units and pre-funded warrant units, resulting in gross proceeds of approximately $6.9 million, and also issued Representative's Warrants to purchase up to 172,538 shares of Common Stock. ($6.9M proceeds)

S-1 filing: This is an S-1 filing for a clinical stage biotechnology company developing genetic medicines and proprietary genetically-engineered oncolytic viruses.

8-K filing: Stock split 1-for-12 | Outstanding: 36,320,580 → 3,026,715

S-3 filing: This prospectus relates to the resale or other disposition from time to time by the selling stockholders of 6,595,000 shares of common stock issuable on the exercise of Series H common stock purchase warrants, exercisable at an exercise price of $0.70 per share, exercisable commencing on January 10, 2026, through the date that is the five years and six month anniversary of the initial exercise date.

8-K filing: Calidi Biotherapeutics, Inc. entered into an inducement offer letter agreement with warrant holders to exercise existing warrants for up to 6,595,000 shares of common stock at a reduced exercise price of $0.70, with gross proceeds expected to be approximately $4.6 million. ($4.6M proceeds)

S-1 filing: This is an S-1 filing for Calidi Biotherapeutics, Inc. related to the offering of common stock issuable upon the exercise of warrants by selling stockholders.

10-Q filing | 31.8M shares outstanding

8-K filing: Calidi Biotherapeutics, Inc. completed a registered direct offering and concurrent private placement on March 31, 2025, issuing 3,325,000 shares of common stock, pre-funded warrants to purchase 2,728,000 shares, and Series G common stock purchase warrants to purchase up to 6,053,000 shares, resulting in gross proceeds of approximately $3.9 million. ($2.16M proceeds)

10-K filing | 28.5M shares outstanding

8-K filing: Calidi Biotherapeutics, Inc. entered into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. to issue and sell 5,000,000 shares of common stock at a purchase price of $0.85 per share, with the closing of the offering on January 10, 2025, and gross proceeds of $4.25 million. ($4.25M proceeds)

S-3 filing: Calidi Biotherapeutics, Inc. files an S-3 to offer common stock, preferred stock, warrants, or a combination of these securities, or units, up to a total offering price of $25,000,000.

S-1 filing: This S-1 filing includes the offering of common stock by selling stockholders, including shares issuable upon exercise of various warrants and shares issued to placement agents and other parties.

8-K filing: Calidi Biotherapeutics, Inc. completed a public offering of 4,437,869 shares of common stock at a purchase price of $1.69 per share, resulting in gross proceeds of approximately $7.5 million before deducting fees and expenses. ($7.5M proceeds)

10-Q filing | 13.1M shares outstanding

8-K filing: Calidi Biotherapeutics, Inc. completed a registered direct offering and concurrent private placement on October 24, 2024, issuing 2,050,000 shares of common stock at $1.00 per share and warrants to purchase up to 4,100,000 shares of common stock, resulting in gross proceeds of approximately $2,050,000. ($2.05M proceeds)

S-3/A filing: Calidi Biotherapeutics, Inc. may offer common stock, preferred stock, warrants, or a combination of these securities, or units, up to a total offering price of $25,000,000.

S-3 filing: Calidi Biotherapeutics, Inc. may offer common stock, preferred stock, warrants, or a combination of these securities up to a total offering price of $25,000,000.

10-Q filing | 8.1M shares outstanding

8-K filing: Calidi Biotherapeutics, Inc. sold 698,812 shares of Common Stock to Dr. Ronald Rigor at a purchase price of $1.431 per share and warrants to purchase 600,000 shares of the Company's common stock at an exercise price of $1.90, for an aggregate purchase price of $1,000,000. ($1.0M proceeds)

8-K filing: Stock split 1-for-10 | Outstanding: 50,924,284 → 5,092,428

8-K filing: Calidi Biotherapeutics closed transactions related to the inducement of warrant exercises, issuing new Series D warrants to purchase up to 10,698,000 shares of common stock and warrants to Ladenburg Thalmann to purchase up to 534,900 shares of common stock, with the net proceeds intended for clinical programs and operating expenses.

8-K filing: Calidi Biotherapeutics, Inc. entered into an inducement offer letter agreement with 9 holders of its existing Series B and Series C unit purchase warrants, who exercised their warrants to purchase up to 10,698,000 shares of the Company's common stock, resulting in gross proceeds of approximately $2.1 million. ($2.1M proceeds)

10-Q filing | 50.9M shares outstanding

S-1/A filing: This S-1/A filing details an offering of common stock and pre-funded warrants, along with associated warrants, with the net proceeds intended for working capital, general corporate purposes, and clinical trials, and potentially to repay promissory notes.

S-1/A filing: This S-1/A filing details an offering of common stock units and pre-funded warrant units to raise capital for working capital, general corporate purposes, and pre-clinical and clinical trials.

S-1/A filing: The filing relates to the offering of placement agent warrants to purchase common stock.

S-1/A filing: This S-1/A filing outlines a proposed offering of common stock units and pre-funded warrants to fund working capital, general corporate purposes, and clinical trials.

10-K filing | 35.5M shares outstanding

8-K filing: Calidi Biotherapeutics, Inc. settled a dispute with physicians by issuing 200,000 restricted shares of common stock and 400,000 warrants to purchase restricted shares with an exercise price of $1.32.

S-1/A filing: Calidi Biotherapeutics is filing an S-1/A registration statement to offer 10,000,000 shares of common stock along with warrants, and pre-funded warrants to certain purchasers, with the proceeds intended for working capital, general corporate purposes, and pre-clinical and clinical trials.

S-1 filing: Calidi Biotherapeutics, Inc. is offering common stock, common warrants (Series A and Series B), and pre-funded warrants. The net proceeds from this offering will be used for working capital and general corporate purposes, and pre-clinical and clinical trials.

S-1/A filing: This is an S-1/A filing for offering shares of common stock through warrants and by selling securityholders.

S-1/A filing: This is an S-1/A filing for shares of common stock offered upon exercise of public warrants and securities offered by selling securityholders.

8-K filing: Calidi Biotherapeutics, Inc. entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) where the Company may sell up to $25,000,000 of its shares of Common Stock to Yorkville, and issued 250,000 Commitment Fee Shares to Yorkville.

S-1/A filing: This is an S-1/A filing for shares of common stock offered by the company and selling securityholders, including shares issuable upon exercise of public and private placement warrants.

10-Q filing | 35.4M shares outstanding

8-K filing: Andrew Jackson was granted 300,000 incentive stock options to purchase Company common stock as part of his employment agreement as Chief Financial Officer.

S-1 filing: This S-1 filing includes the offering of common stock issuable upon exercise of public warrants, shares of common stock by selling securityholders, and private placement warrants to purchase shares of common stock.

10-Q filing | 4.1M shares outstanding

10-Q filing | 4.1M shares outstanding

10-K filing | 4.1M shares outstanding

10-Q filing | 4.1M shares outstanding

10-Q filing | 23.0M shares outstanding

10-Q filing | 23.0M shares outstanding

10-K filing | 23.0M shares outstanding

10-Q filing | 23.0M shares outstanding

S-1/A filing: This S-1/A filing details the company's capitalization as of June 30, 2021, adjusted to reflect the amended certificate of incorporation, the sale of units in the offering, the sale of private placement warrants, and the application of net proceeds. It also mentions a forward purchase agreement with Franklin for 5,000,000 shares of Class A common stock plus warrants.

S-1 filing: This S-1 filing describes the initial public offering of Class A common stock, including the sale of units, private placement warrants, and a forward purchase agreement for additional shares and warrants, with Guggenheim Securities as underwriter.